DeCure for Mayer-Rokitansky-Küster-Hauser syndrome type 2
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Mayer-Rokitansky-Küster-Hauser syndrome type 2 — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMayer-Rokitansky-Küster-Hauser syndrome type 2 maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for mayer-rokitansky-küster-hauser syndrome type 2 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
HNF1 homeobox B (HNF1B) — HNF1B is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 2H8R · 3.2 Å · ligand none (apo structure). Experimental structure, not a prediction.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Obstetrics Gynecology and Reproduction · 2023 · 1 citations · open access
Mayer–Rokitansky–Küster–Hauser syndrome
AbstractThe Mayer–Rokitansky–Küster–Hauser (MRKH) syndrome is an instructive story not only from a historical but also a gnoseological perspective. The mechanisms of embryogenesis as well as multiple aspects for correction of this syndrome remain enigmatic and unsolved. Here, we attempted to organize and detail striking issues related to MRKH syndrome.
Journal of Ayurveda and Integrated Medical Sciences · 2019 · 0 citations · open access
A Clinical Case of Beejabhagavayava Dushti managed with Ayurvedic approach
AbstractPresent days, there is a rapid increase in number of genetic disorders due to various causes. Mayer-Rokitansky-Kuster-Hauser syndrome (MRKH syndrome) is a congenital condition due to mullerian agenesis. This can be correlated with Yonivyapats such as Suchimukhi, Shandi, Antarmukhi and Jataharinis like Shushkarevati, Katambhara. In this work, once such case of a female patient, aged 19 years, presenting with primary amenorrhea is discussed. Rationality in therapeutic approach by implementing the classical principles, along with the surgical aid is also presented which eventually succeeded in treating her.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
